Journal
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES D-THE STATISTICIAN
Volume 49, Issue -, Pages 135-156Publisher
BLACKWELL PUBL LTD
DOI: 10.1111/1467-9884.00227
Keywords
Bayesian inference; bioequivalence; cross-over trials; frequentist inference; model checking; multiplicity; randomization; sequential trials
Categories
Ask authors/readers for more resources
Drug development is a highly regulated business. Statistics plays an important part in measuring and reporting the efficacy and tolerability of pharmaceuticals and this is reflected in American, European, Japanese and international guidelines of some considerable detail which cover the way in which clinical trials are to be planned, run and analysed, The dominant framework for analysis is frequentist but Bayesian approaches are becoming more popular. Some controversial issues in drug development are considered in the light of the International Conference on Harmonisation's 1999 international statistical guidelines to see whether any Bayes-frequentist consensus is possible.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available